Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472089 | 0.86 | MIF (0.43) | MIFALDH1A1ALOX15TSHRPOLB | |
| SCHEMBL17992473 | 0.86 | MIF (0.41) | MIFALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL11835168 | 0.84 | MIF (0.44) | MIFALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL4464054 | 0.79 | ALDH1A1 (0.41) | MIFALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL9491308 | 0.79 | MIF (0.37) | MIFALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL3784429 | 0.78 | TSHR (0.40) | MIFALDH1A1ALOX15TSHRPOLB | |
| SCHEMBL12730995 | 0.77 | HTT (0.38) | MIFALDH1A1ALOX15TSHRPOLB | |
| SCHEMBL25822223 | 0.77 | MIF (0.36) | MIFALDH1A1ALOX15HSD17B10MEN1 | |
| SCHEMBL13406439 | 0.77 | MIF (0.41) | MIFALDH1A1ALOX15TSHRHSD17B10 | |
| SCHEMBL7212025 | 0.76 | MEN1 (0.40) | MIFMEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664414-B2 | Process for producing epoxy compound | SHOWA DENKO K.K. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20120029217-A1 | PROCESS FOR PRODUCING EPOXY COMPOUND | SHOWA DENKO K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2412712-A1 | METHOD FOR PRODUCING EPOXY COMPOUND | Showa Denko K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029217-A1 | PROCESS FOR PRODUCING EPOXY COMPOUND | NOX4, NOX5, NOXO1 | MIF 4003/4885ALDH1A1 1104/4885ALOX15 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.